Table 1.
Total n = 684 |
Not vaccinated n = 580 (84.8%) |
Fully vaccinated n = 104 (15.2%) |
p | |
---|---|---|---|---|
Demographic characteristics | ||||
Age, years | 69 [55–80] | 67 [53–79] | 78 [69–84] | < 0.001 |
Male sex, n (%) | 398 (58.2) | 334 (57.6) | 64 (61.5) | 0.452 |
Caucasian, n (%) | 600 (87.7) | 502 (86.5) | 98 (94.2) | 0.566 |
Latin/hispanic, n (%) | 24 (3.5) | 22 (3.8) | 2 (1.9) | |
Other, n (%) | 60 (8.7) | 56 (9.7) | 4 (3.8) | |
Underlying comorbidities | ||||
Hypertension, n (%) | 300 (43.9) | 245 (42.2) | 55 (52.9) | 0.044 |
Stroke, n (%) | 33 (4.8) | 26 (4.5) | 7 (6.7) | 0.325 |
AMI, n (%) | 70 (10.2) | 48 (8.3) | 22 (21.1) | < 0.001 |
Diabetes, n (%) | 133 (19.4) | 104 (17.9) | 29 (27.9) | 0.018 |
Cardiovascular diseases n (%) | 135 (19.7) | 96 (16.5) | 39 (37.5) | < 0.001 |
COPD, n (%) | 64 (9.4) | 41 (7.1) | 23 (22.1) | < 0.001 |
History of cancer, n (%) | 58 (8.5) | 38 (6.6) | 20 (19.2) | < 0.001 |
CKD, n (%) | 48 (7) | 35 (6) | 13 (12.5) | 0.017 |
Chronic liver disease, n (%) | 15 (2.2) | 9 (1.6) | 6 (5.8) | 0.007 |
Age-adjusted Charlson score | 3 [1–4] | 3 [1–4] | 4 [3–6] | < 0.001 |
Laboratory data | ||||
Haemoglobin, g/dL | 13.5 [12.0–14.7] | 13.7 [12.2–14.9] | 12.9 [11.3–14.1] | 0.005 |
CRP, mg/L | 52.9 (29.2–84.2) | 52.2 [27.1–82.1] | 60.6 [35.9–102.8] | 0.018 |
LDH, U/L | 293 [235–380] | 297 [246–397] | 263 [215–338] | 0.002 |
Leukocytes count, 103/µL | 6.21 [4.65–8.72] | 6.1 [4.51–8.73] | 6.64 [4.65–8.7] | 0.382 |
Platelets,103/µL | 186 [144–247] | 186 [146–239] | 183 [135–260] | 0.910 |
D-Dimer, ng/µL | 320 [211–616] | 314 [214–606] | 383 [196–690] | 0.562 |
GPT, U/L | 29 [19–49] | 30 [20–51] | 24 [17–43] | 0.086 |
GOT, U/L | 44 [19–49] | 44 [34–63] | 39 [29–60] | 0.086 |
Creatinine, mg/dL | 0.9 [0.7–1.2] | 0.8 [0.7–1.1] | 1 [0.8–1.5] | < 0.001 |
Procalcitonin, µg/L | 0.17 [0.07–0.63] | 0.17 [0.07–0.73] | 0.22 [0.18–0.26] | 0.636 |
Ferritin, ng/mL | 339 [186–692] | 357 [182–708] | 314 [305–442] | 0.960 |
Pharmacological treatments | ||||
Remdesivir, n (%) | 174 (25.4) | 169 (29.1) | 5 (4.8) | < 0.001 |
Heparin profilaxis, n (%) | 561 (82) | 479 (82.6) | 82 (78.8) | 0.360 |
Corticosteroid treatment, n (%) | 579 (84.6) | 495 (85.3) | 84 (80.8) | 0.233 |
Biological immunomodulator, n (%) | 49 (7.2) | 42 (7.2) | 2 (1.9) | 0.024 |
Monoclonal antibodies, n (%) | 50 (7.3) | 22 (3.8) | 28 (26.9) | < 0.001 |
Continuous variables are expressed as median [IQR] and compared with Mann–Whitney U test, while categorical data are expressed as n (%) and compared with Chi-square test
COPD chronic obstructive pulmonary disease, AMI acute myocardial infarction, CKD chronic kidney disease, CRP C-reactive protein, LDH lactate dehydrogenase, GOT glutamic–oxalacetic transaminase, GPT glutamate–pyruvate transaminase. History of cancer was defined as a cancer diagnosis in the last 5 years